India’s biotech sector is at a critical juncture, facing challenges in securing long-term capital due to uncertain domestic markets and lengthy R&D timelines. Despite historical caution within Indian pharma towards novel drug development, recent successes—like the IGI-AbbVie deal and advancements by Eyestem Research—signal a transformative shift towards being a hub for cost-efficient, breakthrough innovation. Initiatives like Biopharma SHAKTI aim to de-risk the clinical ecosystem by enhancing infrastructure and regulatory frameworks. To foster early-stage innovation, experts advocate for synchronizing efforts among government, academia, and industry while addressing capital retention and exit opportunities. The next decade is poised to propel India into a global leader in biopharma innovation.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospectrumindia.com/views/17/27715/struggle-for-long-term-biotech-capital-persists-due-to-a-lack-of-assured-domestic-markets.html
